non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA
Treatment Guideline Chart

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Non-Hodgkin's Lymphoma References

  1. Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014 Feb;74(2):263-271. doi: 10.1007/s40265-014-0178-8. Accessed 11 Aug 2014. PMID: 24464309
  2. Brown JR, Freedman AS. Overview of the pathobiology of the non-Hodgkin lymphomas. UptoDate. http://www.uptodate.com/contents/overview-of-the-pathobiology-of-the-non-hodgkin-lymphomas. Jan 2014. Accessed 18 Feb 2014.
  3. Freedman AS, Friedberg JW, Aster JC. Clinical presentation and diagnosis of the non-Hodgkin lymphomas. UptoDate. http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma?source=search_result&search=non+hodgkins+lymphoma&selectedTitle=3~150. Jan 2014. Accessed 21 Feb 2014.
  4. National Cancer Institute. National Cancer Institute: PDQ® Adult Non-Hodgkin Lymphoma Treatment. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional. Jan 2014. Accessed 22 Jan 2014.
  5. National Cancer Institute. National Cancer Institute: PDQ® Childhood Non-Hodgkin Lymphoma Treatment.. National Cancer Institute. http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessional. Aug 2013. Accessed 22 Jan 2014.
  6. National Cancer Institute. Drugs approved for non-hodgkin lymphoma. National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/non-hodgkin. Dec 2013. Accessed 22 Jan 2014.
  7. National Comprehensive Cancer Network Non-Hodgkin’s Lymphomas Panel. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): Non-hodgkin’s lymphomas. Version 1. National Comprehensive Cancer Network (NCCN). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. 2014. Accessed 22 Jan 2014.
  8. National Institute of Neurological Disorders and Stroke. NINDS Progressive multifocal leukoencephalopathy information. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/pml/pml.htm. Feb 2014. Accessed 17 Mar 2014.
  9. Roschewski MJ, Wilson WH. Non-hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2014:2033-2059.e8.
  10. Sharma M, Mannan R, Madhukar M, et al. Immunohistochemical (IHC) analysis of non-Hodgkin’s lymphoma (NHL) spectrum according to WHO/REAL classification: a single centre experience from Punjab, India. J Clin Diagn Res. 2014 Jan;8(1):46-49. http://www.jcdr.net/articles/PDF/3988/14-8173_F(DK)_PF1(RKH)_PFA(H).pdf. Accessed 21 Feb 2014. PMID: 24596721
  11. US Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications. US Food and Drug Administration. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. 2014. Accessed 11 Aug 2014.
  12. National Comprehensive Cancer Network Non-Hodgkin’s Lymphomas Panel. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): Non-hodgkin’s lymphomas. Version 1.2016. NCCN website. http://www.nccn.org/. Dec 2015. Accessed 25 Apr 2016.
  13. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-hodgkin's lymphomas. Version 3.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. 2016.
  14. National Institute for Health and Care Excellence. Non-Hodgkin's lymphoma: diagnosis and management. NICE website. https://www.nice.org.uk/guidance/ng52/resources/nonhodgkins-lymphoma-diagnosis-and-management-1837509936325. Jul 2016.
  15. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep;32(27):3059-3067. doi: 10.1200/JCO.2013.54.8800. PMID: 25113753
  16. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28(Suppl 4):iv62-iv71. doi: 10.1093/annonc/mdx223. PMID: 28881919
  17. National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ®) - health professional version. National Cancer Institute. https://www.cancer.gov/. 18 Sep 2019.
  18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): B-cell lymphomas. Version 1.2020. NCCN. https://www.nccn.org/. 22 Jan 2020.
  19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Chronic lymphocytic leukemia/small lymphocytic leukemia. Version 4.2020. NCCN. https://www.nccn.org/. 20 Dec 2019.
  20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Hairy cell leukemia. Version 1.2020. NCCN. https://www.nccn.org/. 23 Aug 2019.
  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Primary cutaneous lymphomas. Version 1.2020. NCCN. https://www.nccn.org/. 6 Jan 2020.
  22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): T-cell lymphomas. Version 1.2020. NCCN. https://www.nccn.org/. 6 Jan 2020.
  23. Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Jun;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133. PMID: 29878045
  24. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. PMID: 31912792
  25. Ansell SM. Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc. 2015 Aug;90(8):1152-1163. doi: 10.1016/j.mayocp.2015.04.025. PMID: 26250731
  26. Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and treatment. Am Fam Physician. 2020 Jan;101(1):34-41. https://www.aafp.org/. PMID: 31894937
  27. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: B-cell lymphomas. Version 4.2021. NCCN. https://www.nccn.org/. 05 May 2021.
  28. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Primary cutaneous lymphomas. Version 2.2021. NCCN. https://www.nccn.org/. 04 Mar 2021.
  29. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: T-cell lymphomas. Version 1.2021. NCCN. https://www.nccn.org/. 05 Oct 2020.
  30. Wang Z, Zheng Q, Zhang H, et al. Ontak-like human IL-2 fusion toxin. J Immunol Methods. 2017 Sep;448:51-58. doi: 10.1016/j.jim.2017.05.008. PMID: 28551309
Editor's Recommendations
Special Reports